On-Sight Interview with Todd Brady, President & CEO, Aldeyra at OIS@AAO 2019

In a one-on-one, Todd C. Brady, MD, PhD, talks with OIS@AAO’s Ehsan Sadri, MD, FACS, about reactive aldehyde species (RASP) — reactive molecules that covalently bind to cellular biomolecules, disrupting their function and activating pro-inflammatory mediators — and how Aldeyra is leveraging this technology in ophthalmology. REGISTER for our next ophthalmology conference today http://ois.net/register.